BioLineRx (NASDAQ:BLRX) and Hemispherian AS announced encouraging preclinical data for their oncology candidate GLIX1, showcasing the experimental drug’s potential to combat glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.
ECARX Holdings (NASDAQ:ECX) reported a 22% decline in first-quarter revenue as vehicle launch timelines shifted, though sweeping operational cost reductions allowed the automotive intelligence developer to narrow its losses and post positive adjusted EBITDA.
RADCOM (NASDAQ:RDCM) reported a 12% increase in first-quarter revenue and expanding profit margins, though the strong financial results were paired with the sudden resignation of five board directors on the eve of a highly contested shareholder showdown.
Cameron Dawson, CIO at NewEdge Wealth, sees the pullback in tech stocks as "perfectly normal and perfectly prudent," but warns that "a simple correction in those names back to trend could be damaging for the overall market-cap weighted index."
Eagle Materials (NYSE:EXP) reported record-high revenues for both the fourth quarter and full fiscal year 2026, driven by resilient pricing across its cement and wallboard segments, even as inflationary pressures trimmed net margins.
Thermon Group Holdings (NYSE:THR) reported record revenue for fiscal year 2026, driven by robust industrial process heating demand, even as one-time transaction costs tied to its upcoming merger temporarily compressed bottom-line profits.
Boston Scientific (NYSE:BSX) announced that the pivotal clinical trial for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy (IVL) Catheter met its primary safety and effectiveness endpoints, clearing a major hurdle for regulatory submission.
Canaan (NASDAQ:CAN): reported first-quarter revenue in line with its previously issued guidance, anchored by an expansion of its self-mining operations and strategic infrastructure acquisitions despite a challenging environment for hardware sales.
US President Donald Trump said he called off a new bombardment of Iran planned for Tuesday after Persian Gulf allies wanted more time to pursue diplomacy. Tyler Kendall reports on Bloomberg Television.
Natural Alternatives International (NASDAQ:NAII) reported a double-digit increase in third-quarter revenues, but persistent manufacturing underutilization and overhead costs kept the nutritional supplement manufacturer in the red.
Relay Therapeutics (NASDAQ:RLAY) announced positive initial data from an ongoing mid-stage clinical trial evaluating its precision medicine candidate, zovegalisib, in patients with rare genetic vascular anomalies.
Bilibili (NASDAQ:BILI) reported first-quarter financial results that met revenue expectations and turned a net profit, powered by robust advertising growth and heightened user engagement that cushioned its cooling mobile games division.
_1402791_640x360_2500589123916-640x360.webp&w=3840&q=75)
_1402780_640x360_2500593731693-640x360.webp&w=3840&q=75)
